default author photo

Marcello Tiseo

University of Parma

Via Amendola 10

Parma, 43100

United States

SCHOLARLY PAPERS

3

DOWNLOADS

107

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Braf-Mutant Metastatic Non–Small-Cell Lung Cancer: Real World Data from the Italian Biomarker Atlas Database

Number of pages: 25 Posted: 12 Jun 2025
Ospedale Giovanni Paolo II, affiliation not provided to SSRN, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori, affiliation not provided to SSRN, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Careggi University Hospital of Florence - Clinical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), “Vito Fazzi” Hospital, University of Verona - Hospital Trust, Cardinal Massaia Hospital, Pederzoli Hospital-Peschiera del Garda, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, ASST Papa Giovanni XXIII, Regione Veneto - Azienda Ulss 3 Serenissima, affiliation not provided to SSRN, affiliation not provided to SSRN, San Giovanni di Dio Hospital,, affiliation not provided to SSRN, Università degli Studi di Genova, University of Florence, affiliation not provided to SSRN, University of Verona, affiliation not provided to SSRN, University of Pavia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ospedale Michele e Pietro Ferrero - Verduno, affiliation not provided to SSRN, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Gynecologic Unit, University of Naples Federico II, University of Turin, University of Turin and affiliation not provided to SSRN
Downloads 39 (1,196,171)

Abstract:

Loading...

BRAF mutations, dabrafenib, trametinib, immunotherapy, BRAF V600E, NSCLC, real-world evidence.

2.

Low Ft3/Ft4 Ratio as a Proxy for Muscle Wasting in Patients with Advanced Non-Small Cell Lung Cancer Treated with Upfront Pembrolizumab

Number of pages: 12 Posted: 31 Mar 2025
University of Verona, University of Verona, University of Verona, University of Verona, University of Verona, University of Verona, University of Verona, University of Verona, University of Verona, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, IRCCS Regina Elena National Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Parma, affiliation not provided to SSRN, University of Verona, University of Verona - Hospital Trust and University of Verona
Downloads 39 (1,196,171)

Abstract:

Loading...

Non-Small Cell Lung Cancer (NSCLC), Muscle Wasting, Immune Checkpoint Inhibitors (ICIs), Thyroid Hormones, Sarcopenia, Body Composition.

3.

CHIMERA: a phase II study of neoadjuvant pembrolizumab in combination with cisplatin or carboplatin and pemetrexed followed by surgery and adjuvant pembrolizumab in resectable pleural mesothelioma

Number of pages: 10 Posted: 07 Jan 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Università degli Studi di Bari “Aldo Moro” (UNIBA), affiliation not provided to SSRN, Humanitas Gavazzeni, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ferrara, affiliation not provided to SSRN, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Padova - Department of Cardiac, Thoracic, Vascular Science and Public Health, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 29 (1,332,057)

Abstract:

Loading...

Pleural Mesothelioma, Immunotherapy, perioperative, pleurectomy, multimodality